Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Two-thirds of Congress members received pharma donations in 2020

By Brian Buntz | June 9, 2021

U.S. Capitol

Image from Pixabay

More than two-thirds of Congress received campaign funding from pharmaceutical companies in the 2020 election, according to STAT.

Industry-friendly senators such as Thom Tillis (R-N.C.) and Chris Coons (D-Del.) received some of the largest sums. Influential representatives such as Richard Hudson (R-N.C.), Robin Kelly (D-Ill.), Kurt Schrader (D-Ore.) and Anna Eshoo (D-Calif.) also received significant amounts.

Pfizer (NYSE:PFE), Amgen (NSDQ:AMGN) and AbbVie (NYSE:ABBV) are among the most prominent donors. Last year, Pfizer gave $3.5 million to federal candidates, parties and outside groups, while Amgen and AbbVie spent about $2 million.

Senate Finance Committee Chair Ron Wyden has recently launched an investigation into AbbVie’s drug pricing and financial practices.

The pharmaceutical and health products industry are among the most consistent donors to federal campaign contributions, according to OpenSecrets.

Although the GOP tends to offer more solid support for the pharmaceutical industry than Democrats, the industry donated more last year to Democrats. In 2020, Democrats in Congress hauled in $11.9 million from the pharma sector while Republicans collected $7.7 million.

According to OpenSecrets, the pharma industry spent $28.4 million in total contributions last year. By contrast, the industry spent $17.2 million on such donations in 2018.

Although the pharma industry’s lobbying spending has fluctuated, it has increased significantly in the past two decades. 

A 2020 study in JAMA concluded that the pharma and health product industry spent $4.7 billion on campaign contributions and lobbying from 1999 to 2018. The paper concluded that such funding could stymie “government efforts to lower drug costs and other legislative and regulatory initiatives.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Pfizer logo
Pfizer CEO tests positive for COVID-19
Pfizer logo
Pfizer and BioNTech seek EMA authorization for COVID-19 vaccination in young children
Pfizer logo
FDA allows pharmacists to prescribe Paxlovid 
vaccine
Will COVID-19 vaccines be updated by fall? 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards